Actinogen Medical Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ACW.AX | NP5.F | AVXL | XINT.ST | ACTU | PRTC.L | |
|---|---|---|---|---|---|---|
| Market cap | 166.59M | 205.50M | 116.80M | 124.45M | 20.34M | 302.55M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -4.3 | — | -2.3 | — | -0.6 | -5.1 |
| Price/book | 7.2 | -17.9 | 1.0 | -4.5 | 9.0 | 1.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +5.26% | −38.08% | −83.58% | −60.80% | −94.58% | −2.36% |
| Today | +7.50% | −0.50% | +5.00% | +0.35% | +5.69% | −0.64% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All ACW.AX news ›Readout Countdown: Is Actinogen (ASX:ACW) Ready for Its Alzheimer's Trial Results?
Rate Decision Day: How Is Zip Co (ASX:ZIP) Squaring Up? Software Bruises: Where Does Iress (ASX:IRE) Turn Next? Recruitment for XanaMIA closed earlier, and all patient visits are complete. The company confirmed in late October that the…
Transcript : Actinogen Medical Limited - Special Call
Presenter SpeechSteven Gourlay My pleasure as the CEO of Actinogen to welcome everybody here today. We are very thrilled to have Professor Sabbagh from the U.S.A., who is a very experienced... Transcript : Actinogen Medical Limited -…
Actinogen Medical Limited: Total Return chart (Dividends reinvested) - Australian S.E. stock market
See the history of Actinogen Medical Limited, with dividends reinvested. (Total Return chart) ACW Stock market Total Return chart Actinogen Medical Limited Biotechnology & Medical Research All financial news and data tailored to specific…
Actinogen Medical Limited: Relative Strength Chart - Stock Australian S.E.
Compare Actinogen Medical Limited with the company of your choice via a Relative Strength chart. Real-time ACW price, Australian S.E. stock exchange Relative Strength Chart Actinogen Medical Limited Biotechnology & Medical Research All…
Actinogen Medical closes September quarter with XanaMIA readout in sight
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) closed the September quarter with its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial on track for topline results in November and a pro-forma cash position of around A$21.9 million. The…
Actinogen Medical enters ‘database lock’ to process XanaMIA’ data and confirm findings
A Master of Communications and Media Studies graduate with a keen interest in journalism and news. Shannon is a motivated, hardworking individual who thrives in collaborative environments and has practical experience in media analysis,…
Canaccord Genuity Sticks to Their Buy Rating for Actinogen Medical (ATGGF)
Canaccord Genuity analyst Shane Storey maintained a Buy rating on Actinogen Medical yesterday and set a price target of A$0.08. The company’s shares closed last Thursday at A$0.04. According to TipRanks, Storey is a 3-star analyst with an…
Actinogen Medical Limited (ASX:ACW): How Brain Cortisol Research Shapes Its Alzheimer’s Trial
Xanamem remains an investigational therapy and is not approved for routine medical use. The mechanism provides a scientific rationale for research; any claim about clinical effectiveness must be established through trial results. In August…
Actinogen Medical Receives Independent DMC Positive Recommendation for Phase 2b/3 Alzheimer's Disease Trial, Shares Jump 10%
Actinogen Medical received a positive recommendation from the XanaMIA phase 2b/3 Alzheimer's disease trial's independent data monitoring committee to continue the trial without amendment,... Biotechnology & Medical Research Actinogen…
Actinogen Medical Limited Completes Final Participant Visit for Xanamia Phase 2B/3 Alzheimer?S Disease Clinical Trial
Actinogen Medical Limited announced that, following the final participant visit on 22 September in the USA, topline results for the XanaMIA phase 2b/3 Alzheimer?s disease clinical trial remain on... Actinogen Medical Limited announced…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com5
- markets.businessinsider.com2
- proactiveinvestors.com2
- kalkine.com.au1
- kalkinemedia.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.